You are here:

capsaicin (Qutenza)

Advice

following a re-submission:

capsaicin (Qutenza®) is accepted for restricted use within NHS Scotland.

Indication under review: For the treatment of peripheral neuropathic pain in non-diabetic adults either alone or in combination with other medicinal products for pain.

SMC restriction: to use in patients who have not achieved adequate pain relief from, or have not tolerated, conventional first and second line treatments.

A phase IV, open-label, randomised, controlled study showed that capsaicin patch was non-inferior to an oral analgesic in adult patients with peripheral neuropathic pain.
 

Drug Details

Drug Name: capsaicin (Qutenza)
SMC Drug ID: 673/11
Manufacturer: Astellas Pharma Ltd
Indication: For the treatment of peripheral neuropathic pain in non-diabetic adults either alone or in combination with other medicinal products for pain.
BNF Category:
Sub Category: 10.3 Drugs for the relief of soft tissue inflamation
Submission Type: Resubmission
Status: Restricted
Date Advice Published: 13 October 2014

Archived Advice

Full submission 7 February 2011

Back